Abstract:

Objective To investigate the effects of atorvastatin on serum levels of soluble receptor for advanced glycation end products(sRAGE) and endogenous secretory receptor for advanced glycation end products(esRAGE) in patients with unstable angina. Methods Forty patients with unstable angina (UA group) were selected, and 20 mg/d of atorvastatin was orally administrated. Venous blood samples were obtained before treatment and 3 months after treatment, and serum total cholesterol (TC), triglyceride (TG), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol(HDL-C), glucose, glycated hemoglobin(HbA1C), sRAGE and esRAGE were measured. Another 20 age and gender matched healthy subjects were served as control group. Results Before treatment, serum levels of TC and LDL-C in UA group were significantly higher than those in control group (P<0.05), and serum levels of sRAGE and esRAGE in UA group were significantly lower than those in control group (P<0.05, P<0.01), while there was no significant difference in the other parameters between groups (P>0.05). After treatment with atorvastatin for 3 months, serum levels of glucose and HbA1C in UA group were not significantly different from those before treatment (P>0.05), serum levels of TC and LDL-C were significantly lower than those before treatment （P<0.05), and serum levels of sRAGE and esRAGE were significantly higher than those before treatment (P<0.05). Linear correlation analysis revealed that there was a negative correlation between serum level of esRAGE and serum level of LDL-C （r=－0.36，P=0.01）. Conclusion Statins have pleiotropic effects, and atorvastatin can increase serum levels of sRAGE and esRAGE in patients with unstable angina.

Key words: atorvastatin, unstable angina, soluble receptor for advanced glycation end products, endogenous secretory receptor for advanced glycation end products